
Black Cohosh

- Botany
 - Actaea (Cimicifuga) racemosa. A tall perennial shrub native to Eastern USA; roots and rhizomes used
- History
 - Used by Native Americans for women's health problems and a variety of other uses; A component of Lydia Pinkham's elixir,
 - In Europe a special black cohosh extract (Remifemin) has been used since the 1950s for symptoms of menopause and PMS
- Chemistry
 - Contains phytosterin, salicylic acid, tannins, and triterpine glycosides that may be important for activity
 - The triterpine glycosides include acetin, 27-deoxyacetin, and cimicifugoside



Pharmacology

•black cohosh seems to have no effect on uterus or hormone levels(Liske et al. J Women's Health and Gender Based Med. 2002;11:163-174)

•May have central CNS effect on serotonin receptor


•Does not seem to stimulate estrogen receptor dependant tumors in animals or in vitro tumor cell growth. Humans?

Uses


- reduce symptoms associated with menopause
 relieve symptoms of menopause associated with tamoxifen therapy
 PMS
- •dysmenorrhea
- hasten childbirthing

Evidence for relief of menopausal symptoms


- •Early studies with Remifemin show support for reducing hot flashes, etc in menopause
- •well designed studies indicate benefit
- •However, a recent well designed study done here (see slide) showed no effect but Remifemin was not the product tested




Wuttke et al. Maturitas 2003;44:S67-S77; n=62; 40mg/d for 3 months.



Wuttke et al. Maturitas 2003;44:S67-S77; n=62; 40mg/d for 3 months.




Wuttke et al. Maturitas 2003;44:S67-S77; n=62; 40mg/d for 3 months.



Osmers et al. Obstet Gynecol 2005;105:1074-83. N=304; 40mg extract for 12 weeks. (Remifemin)

Above are results in early climateric women



Osmers et al. Obstet Gynecol 2005;105:1074-83. N=304; 40mg extract for 12 weeks.

Above are results in late climateric women

Nappi et al. <u>Gynecol</u> <u>Endocrinol</u> <u>2005;20:30-</u> <u>5</u>. n=64




Figure 1. Mean (\pm standard deviation) number of hot flushes per day recorded in a diary throughout the 3 months of treatment and mean Greene score for vasomotor symptoms recorded monthly in postmenopausal women treated with either *Cimicifuga racemosa* (CR) or low-dose transdermal estradiol (TTSE₂). Significance (*) is reported in the text.





Figure 2. Mean (\pm standard deviation) Symptom Rating Test score for anxiety and depression recorded before and after 3 months of treatment with either *Cimicifuga racemosa* (CR) or low-dose transdermal estradiol (TTSE₂). Significance (*) is reported in the text.

TTSE₂

Adjusted mean number of vasomotor symptoms per day, by study group Newton, K. M. et. al. Ann Intern Med 2006;145:869-879 N=351 for 1 yr



Evidence for help in tamoxifen therapy:

•Results are mixed. One study showed no benefit

•Jacobson et al. J Clin Oncol 2001;19:2739-2745 n=85; cohosh product NOT DESCRIBED

•Munoz and Pluchino. Maturitas 2003;44:S59-S65. N=136; cohosh 20mg/d Menofem[®] for 12 months.

•Table 4

Table 4			
Hot flushes reduction	by Cl	R BNO	1055

Hot flushes	Usual-care group ^a $(n = 46)$	Intervention group ^b $(n = 90)$
Severe	34 (73.9%)	22 (24.4%)
Moderate	12 (26.1%)	26 (28.9%)
None	_	42 (46.7%)

^a Tamoxifen adjuvant therapy.

^b Combined therapy: tamoxifen+CR BNO 1055.

Munoz and Pluchino Maturitas 2003;44:S59-S65. N=136; 12 mos

Safety

- •GI upset, headache, dizziness possible
- •due to possible estrogenic effects, use with caution pregnancy
- •in vitro does not stimulate breast cancer cells (in contrast to soy isoflavones) but in vivo the risk is uncertain.
- •several reports of severe liver toxicity (causal?)

Products

•Remifemin (SK Beecham) is a good product that has been used successfully in controlled trials; it is standardized to contain 1mg of 27-deoxyacetin per 20mg tablet.

•1 BID


Black Cohosh

Summary

- Efficacy: conflicting evidence for benefit for relief of menopausal symptoms using products other than Remifemin. Mixed evidence for relief of tamoxifen adverse effects.
- Safety: good but a few case reports of liver toxicity. Safety in women with existing breast cancer is uncertain.
- Drug interactions: weak 2D6 induction?
- Product selection: standardized root extract;
 20mg BID; Remifemin seems to work.
- Questions remaining include
 - What is the risk in breast cancer?
 - What is the risk for hepatotoxicity?

Milk Thistle

- Botany
 - Silybum marianum
 - Asteraceae family (daisy, thistles, artichoke)
- History
 - long used to treat "liver problems
- Chemistry
 - fruits/seeds contain flavonolignans
 - silymarin=crude mixture of flavonolignans; actually is mixture of several e.g. silybinin
 - Seeds generally used



Milk Thistle

- Pharmacology
 - silymarin has strong antioxidant properties
 - has ability to block toxin entry through membranes
 - stimulates liver regeneration; undergoes enterohepatic circulation
 - increases glutathione
 - stimulates ribosomal RNA polymerase
 - has anti-carcinogenic activities in vitro and in animals
- Uses
 - liver cirrhosis
 - hepatitis A,B,C
 - liver toxin poisoning (e.g. Amanita philloides mushroom)

Viral Hepatitis (A or B)

in several studies patients "normalized" hepatic function tests faster in the milk thistle group compared to placebo; shorter hospital stay

Hepatitis C – unknown efficacy; Tanamley et al. (Dig Liver Dis. 2004 Nov;36(11):752-9) were not able to show improvement compared to a multivitamin control at 1 yr (n=141).

A recent crossover study (placebo or milk thistle) for 12 weeks (n=17) showed no benefit (Gordon et al. J Gastroenterol Hepatol 2006;21:275-280).

Toxin and Drug Inducted Hepatitis

both animal and some small patient studies show protective effect of milk thistle or silymarin

A meta-analysis (Am J Med 2002;113:506-15) concluded no strong benefit but more studies needed; animal studies indicate considerable promise for beneficial activities

Alcohol Related Liver Disease

- some improvement in liver function tests compared to placebo in limited studies
- cirrhosis: Pares et al. J. Hepatol 28:615-621, 1998; no effect on survival or clinical course of alcoholics; n=200; 2yr study
- cirrhosis: (Ferenci et al. J. Hepatol 9:105-113, 1989 showed 58% 4yr survival in treated vs 39% placebo (p=0.036); 4 yr study
- Lucena et al. (Int J Clin Pharmacol 2002;40:2-8) showed increase in glutathione and decreased liver peroxidation in patients with alcoholic cirrhosis but no change in routine liver tests in treated compared to placebo. N=60
- Alcoholic cirrhotic diabetics. Velussi et al. 1997;26:871-879.
 N=60. Open label. Improved

Rambaldi et al. Cochrane Database Syst Rev 2005;2:CD003620. For alcoholic and/or hepatitis B or C liver disease, there were trends for benefit on overall mortality and complications and a statistical reduction in liver-related mortality in all trials (RR 0.5, CI 0.29-0.88) but not in high quality trials (RR 0.57, CI 0.28-1.19). "high quality trials are needed"

Milk Thistle

- Cautions
 - Nothing special
- Interactions
 - None of significance reported as yet. Recently shown to not affect indinavir pharmacokinetics or CYP3A4 or P-glycoprotein.
- Products
 - flavonolignans are not water soluble
 - extract used
 - extracts containing at least 70% silymarin are best
 - A lipid complex of silibin has high bioavailability

New Potential Use in Diabetics

randomized, double –blind, placebo controlled trial (n=51) gave milk thistle extract or placebo for 4 months to diabetics. Glycosylated hemoglobin (HbA1c) and lipid profiles improved.

Huseini et al. Phytother Res 2006;20:1036-1039.

Milk Thistle

Summary

- Efficacy: possibly helpful for liver injury due to hepatitis and drugs and alcohol but evidence is weak. Some promise for diabetics
- Safety: good
- Drug interactions: none noted so far.
 None of significance reported as yet.
- Product selection: extract containing 80% silymarin is best
- Dose: 200mg TID
- Questions remaining include
 - Does milk thistle really work for its hepatitis B or C and for alcoholic liver disease? Will it be useful for diabetic patients?

Ginseng

Botany

- •Panax ginseng (Korean or Asian ginseng),
- •Panax quinquefolius (American ginseng)
- •note: Siberian ginseng is different (Eleutherococcus senticosus)
- •steamed and dried product is "red" ginseng vs "white" ginseng which is dried only

•History

•Chemistry-ginsenosides, a series of steroid glycosides. The ratio of these differ between Panax sp.




Fig. 22.10. Steroids associated with ginseng.

•Pharmacology – "adaptogen" is the term that perhaps best describes what ginseng is supposed to accomplish.

•Uses

•immune stimulant - animal and human studies (with flu vaccine) indicate that it may enhance the immune response

•sports performance - mixed results but generally negative

•mental functioning – mixed results but some intriguing results indicate promise for enhancing completion of mental tasks and (in combination with ginkgo) memory

•"improved quality of life" – results of small studies are inconsistent

•cancer prevention - one controversial study in Korea showed preventative effects

•hypoglycemic effects in diabetic patients (e.g. Vuksan et al., Diabetes Care 23:1221-1226,2000, Vuksan et al. Nutr Metab Cardiovasc Dis. 2008;18:46-56.) with use of American ginseng and Panax ginseng (Reay et al. J Psychopharmacol. 2006;20:771-81

•Korean red ginseng in one recent study showed to be helpful in erectile dysfunction

•Common cold. Several studies indicate that a special extract (Cold-FX) showes preventative and treatment benefits

Predy et al. CMAJ 2005;173:1043-1048

Note: special extract of ginseng used that contains polyfuranosyl-pyranosylsaccharides. Product (Cold-FX) available in Canada and USA. An earlier, smaller study showed activity in preventing flu in older adults (McElhaney et al. Am GeriatrSoc. 2004;52:13-19.)

Table 2: Number of colds over the 4-month intervention period*

	Group; no. (%)†			
Outcome	Placebo n = 149	Ginseng extract n = 130	Difference (95% CI)	
Jackson+ colds‡				
No. per person, mean (SD)	0.93 (0.91)	0.68 (0.82)	0.25 (0.04 to 0.45)	
1 cold	95 (63.8)	71 (54.6)	9.1 (-2.4 to 20.7)	
≥ 2 colds	34 (22.8)	13 (10.0)	12.8 (4.3 to 21.3)	
Colds§				
No. per person, mean (SD)	0.99 (1.00)	0.71 (0.83)	0.29 (0.07 to 0.50)	
1 cold	96 (64.4)	73 (56.2)	8.3 (-3.2 to 19.8)	
≥ 2 colds	37 (24.8)	13 (10.0)	14.8 (6.2 to 23.5)	

Note: SD = standard deviation, CI = confidence interval.

*Unless stated otherwise.

 ± 1 + Subjects providing baseline data only (placebo n = 21, ginseng extract n = 23) were excluded from the data analysis.

‡Total symptom score over 2 days > 14.

SDaily total symptom score > 4.

Table 3: Severity, number of days of symptoms and duration of all colds* over the 4-month intervention period per subject reporting cold symptoms

	Group;			
Outcome	Placebo n = 96	Ginseng extract n = 73	Difference† (95% CI)	
Total symptom score	112.3 (102.5)	77.5 (84.6)	1.5 (1.2-2.0)	
Total symptom score per cold	75.9 (68.3)	64.2 (75.1)	1.3 (1.1-1.6)	
Total days with cold symptoms, no.	16.5 (13.8)	10.8 (9.7)	1.6 (1.3-2.0)	
Duration of each cold, d	11.1 (8.1)	8.7 (7.2)	1.3 (1.0-1.7)	

Note: SD = standard deviation, CI = confidence interval.

*Daily total symptom score > 4.

†Statistical analyses were performed on the log-transformed data; differences and confidence intervals were obtained by transforming back to the original scale using antilogs.

•Dose

1-2g/d of dried root

• 200mg/d of a standardized extract of the root containing 4-7% ginsenosides; it is recommended to take for 4 weeks then stop for 1-2 weeks.

Adverse Effects

•much listed but close evaluation indicates wide safety; reports of problems may be associated with poor products and adulterated products

Drug Interactions

• may be CYP inducer (more later)

•Bottom Line

- pick a good product
- maybe useful in diabetes and in geriatric populations
- watch for drug interactions with narrow therapeutic index drugs

Ginseng

Efficacy: huge literature of small, uncontrolled studies; some evidence for applications in geriatric patients (improved "quality of life") and in diabetes and common cold and flu (Cold-FX)

Safety: good; reported problems may be due to poor quality product

- Drug interactions: may precipitate hypoglycemia with insulin or oral hypoglycemics
- Product selection: product should be standardized to deliver about 25mg/dose ginsenosides or about 50mg/d
- **Dose: 200mg per day of extract**

Questions remaining include:


• What, actually is this stuff good for!


St. John's Wort


Botany

- Hypericum perforatum

- History
- Chemistry
 - Hypericin
 - hyperforin







Rutin (flavonoid glycoside)

St. John's Wort

- Pharmacology
 - hypericin
 - antiviral acitivity
 - MAOI ? 1984 study found activity but 3 more recent studies say no
 - hyperforin

more important

- Flavonoids
 - antioxidant
 - MAOI ? But maybe not in vivo
- Other? MAOI, SSRI

St. John's Wort

- Evidence -Depression
 - widely prescribed in Europe for depression
 - Commission E "approved" for this use
 - Commission E- psychological disturbances, depression, anxiety,nervous unrest; topically the oil for bruises,myalgi, burns

St. John's Wort Meta -analysis of 40 randomized trials (Linde et al. Br J Psychiatry. 2005;186:99-107)


- 26 trials =double blind, placebo controlled; 3320 patients
- 14 trials = double blind, compared to standard treatment;
 2283 patients

Linde et al. Br J Psychiatry. 2005 Feb;186:99-107

Study	Hypericum n/N	Placebo n/N	RR (food) 95% CI	RR (fixed) 95% CI			
Restricted to major depression - smaller (less precise) trials							
Hänsgen 1996	35/53	12/54		2.97 (1.74-5.07)			
Kalb 2001	23/37	15/35		1.45 (0.92-2.29)			
Laakmann 1998	24/49	16/49		1.50 (0.92-2.46)			
Lehri 1993	4/25	2/25		— 2.00 (0.40–9.95)			
Schrader 1998	45/80	2/79		3.70 (2.12-6.46)			
Shelton 2001	26/98	19/102		1.42 (0.84-2.40)			
Subtotal (95% CI)	342	344	•	2.06 (1.65-2.59)			
Total events 157 (Hypericur	n), 76 (Placebo)		1				
Test for heterogeneity: χ^2 =		i), P=57.9%	1				
Test for overall effect: Z+6.	29 (P<0.00001)						
Restricted to major depressio	n – larger (more pred	ise) trials					
HDTSG 2002	46/113	56/116		0.84 (0.63-1.13)			
Lecurbier 2002	98/186	80/189		1.24 (1.00-1.54)			
Montgomery 2000	55/123	57/124	+	0.97 (0.74-1.28)			
Philipp 1999	67/106	22/47	+ - -	1.35 (0.96-1.89)			
Volz 2000	46/70	34/70		1.35 (1.01-1.82)			
Witte 1995	34/48	25/49		1.39 (1.00-1.93)			
Subtotal (95% CI)	646	595	•	1.15 (1.02-1.29)			
Total events: 346 (Hypericu	m), 274 (Placebo)		-				
Test for heterogeneity: $\chi^2 =$	0.62, d.f.=5 (P=0.09)	1°=48.0%					
Test for overall effect: Z=2.							
Not restricted to major depre	ession – umaller dess	heerisel trials					
Halama 1991	10/25	0/25		➔ 21.00 (1.30–340.02)			
Hoffmann 1979	19/30	3/30		+ 6.33 (2.09-19.17)			
Osterheider 1992	0/22	0/23		Not estimable			
Quandt 1993	29/44	3/44		9.67 (3.18-29.41)			
Schlich 1987	15/25	3/24		+ 4.80 (1.59-14.50)			
Schmidt 1989	10/20	4/20		2.50 (0.94-6.66)			
Subtotal (95% CI)	166	166		6.13 (3.63–10.38)			
Total events: 83 (Hypericum	(), 13 (Placebo)						
Test for heterogeneity: 21=		l ¹ =16.8%					
Test for overall effect Z=6.							
Not restricted to major depre	tasion - longer (more	precise) trials					
Hübner 1993	14/20	9/20		1.56 (0.89-2.73)			
König 1993	29/55	31/57		0.97 (0.69-1.37)			
Reh 1992	20/25	11/25		1.82 (1.12-2.95)			
Schmidt 1993	20/32	6/33		3.44 (1.59-7.44)			
Sommer 1994	28/50	13/55		2.37 (1.39-4.04)			
Winkel 2000	34/60	17/59		1.97 (1.24-3.11)			
Subtotal (95% CI)	242	249	•	1.71 (1.40-2.09)			
Total events: 145 (Hyperics	m), 87 (Placebo)						
Test for heterogeneity: 21=15.48, d.f.=5 (P=0.008), I1=67.7%							
Test for overall effect: Z=5							
0.1 0.2 0.5 1 2 5 10							
favours placebo favours Hypericum							


Linde et al.						
Br J	Study	Hypericum n/N	Standard antidepressant n/N	RR (fixed) 95% CI	RR (fixed) 95% CI	
_	,	ripencaminin	anodepressant mix	73% CI	KK (fixed) 75% CI	
Psychiatry.	Older antidepressants Bergmann 1993	32/40	28/40		1.14 (0.89-1.48)	
2005	Harrer 1993	27/51	28/51		0.96 (0.67-1.38)	
2005	Phillipp 1999	76/106	70/110	-	1.13 (0.94-1.36)	
Feb;186:99-	Vorbach 1994 Vorbach 1997	42/67 36/107	37/68 41/102	-+•	1.15 (0.87-1.53) 0.84 (0.59-1.20)	
100,100.77	Wheatley 1997	40/87	42/78	_	0.85 (0.63-1.16)	
107	Woelk 2000	68/157	67/167		1.08 (0.83-1.40)	
107	Subtotal (95% CI)	615	616		1.03 (0.93-1.14)	
	Total events: 321 (Hypericum),			ſ		
	Test for heterogeneity: χ ² =5.14 Test for overall effect: Z=0.54	· · · ·				
	rescion overall effect. 2-0.54	((-0.37)				
	Selective serotonin reuptake inhib	itore				
	Behnke 2002	16/35	21/35		0.76 (0.49-1.20)	
	Brenner 2000	7/15	6/15		1.17 (0.51-2.66)	
	HDTSG 2002	46/113	55/111		0.82 (0.61-1.10)	
	Harrer 1999	50/77	57/84	+	0.96 (0.77-1.19)	
	Schrader 2000	57/125	39/114		1.33 (0.97-1.83)	
	van Gurp 2002 Subtotal (95% CI)	20/45 410	22/45 404	-	0.91 (0.58-1.42) 0.98 (0.85-1.12)	
	5 F		101	•	0.90 (0.05-1.12)	
	Total events: 196 (Hypericum), 200 (standard) Test for heterogeneity: χ ² =6.49, d.f.=5 (P=0.26), l ² =23.0%					
	Test for overall effect: Z=0.33 (P=0.74)					
		. ,				
	Total (95% CI)	1025	1020	+	1.01 (0.93-1.10)	
	Total events: 517 (Hypericum),	· · · · · · · · · · · · · · · · · · ·				
	Test for heterogeneity: χ ² =12.53, d.f.=12 (P=0.40), l ² =4.2%					
	Test for overall effect: Z=0.20	(P=0.84)			ment and a second se	
			0.1 0.2	0.5 1 2	5 10	
			favours plac		Hypericum	
			havours par	cebo lavours	r ipencum	

- Linde et al conclusions: more effective than placebo, similar to standard drugs but not for major depression
- Woelk et al. BMJ 321:536-539, 2000. SJW same as imipramine with fewer adverse effects in multicentered German study (n=324) in patients with mild to moderate depression
- Brenner et al. Clin Ther 22:411-419, 2000. SJW same as sertraline in double blind, randomized study (n=30) with mild to moderate depression
- Schrader et al. Int Clin Psychopharmacol 15:61-68,2000. SJW same as fluoxetine with fewer adverse effects in multicentered German study (n=240) in patients with mild to moderate depression
- Szegedi, A et al. BMJ 2005;330:503. SJW same as paroxitine with fewer adverse events. N=244




intention-to-treat.

Schrader et al., Int J Clin Psychopharmacol 15:61-68,2000



•NIH funded study

- •Duke Univ.
- •N=336 with **major** depression
- •1/3 SJW 1/3 SSRI 1/3 placebo
- •3 years



Davidson et al. JAMA 2002;287:1807-1814





Fig 2 Total Hamilton depression scores over time (intention to treat analysis, means and 95% confidence intervals)



Used WS552 containing 5.2% hyperform

bmj**.**com

- Other Uses: less well documented
 - Seasonal Affective Disorders
 - n=20 SAD patients
 - same decrease in Hamilton depression scale with SJW ± light
 - Hypericin antiviral studies
 - hypericin activity against glioma cells
 - SJW long used to heal wounds
 - plant oil has antimicrobial activity

- adverse
 - photosensitivity-animals
 - photosensitivity- humans- in high doses is a risk
 - 1800mg/d + UVA; not at usual doses
 - SSRI drugs contraindicated. Additive effects with imipramine
 - Open study of 3250, Wolk et al 1994
 - 0.5% allergic rxns, 0.6% GI, 0.4% fatigue
 - SJW is a CYP inducer with herbal/drug interactions documented.
 - SJW is a PGP inducer with documented interactions

Summary

- Efficacy: good evidence in mild to moderate depression
- Safety: don't combine with other medications unless under close monitoring; possible photosensitivity
- Drug interactions: a problem. Is a P450 inducer and a p-glycoprotein inducer
- Product selection: want standardized extract containing about 0.3% hypericin or 2-3% hyperforin; 300mg TID for treatment; LI160 and WS1172 extracts are the best studied
- Questions remaining include
 - How best to use this herbal given that there are drug interaction problems

Hypericin and Hyperforin in Eight Brands of St. John's Wort

De Los Reyes and Koda, Am J Health-syst Pharm 59:545-547.2002

•	Hyperifin	0.29	1.89
•	PNC	0.12	0.20
•	Brite-Life	0.22	1.16
•	ShopKo	0.26	0.05
•	Shurfine	0.17	0.29
•	YourLife	0.28	0.19
•	Nature's Balance	e 0.03	0.01
•	Natrol	0.25	0.48

* Usually want 0.3% hypericin and 1-2% hyperform